real-time news and commentary for investors
Tuesday, Sep 24
Inovio talks monoclonal antibodies, DNA plasmid technology, shares rise
- Inovio Pharmaceuticals (INO) announces the publication of a peer-reviewed paper which outlines a study wherein the delivery of a DNA-based monoclonal antibody triggered the generation of antibody molecules "possessing desirable functional activity including high antigen-binding and HIV-neutralization capabilities against diverse strains of HIV viruses for at least 7 days" in mice.
- The company also notes the strategy "resulted in a rapid increase in antibody levels."
- CEO Dr. J. Joseph Kim says what makes him "particularly excited about this new published data is that, although early, the results clearly demonstrate the utility and potential of INO patented DNA plasmid and electroporation technology." (PR)
- INO +7% premarket.